Key Takeaways
- • Blackstone and TPG are in advanced negotiations to acquire Hologic for approximately $17 billion including debt, representing one of the largest private equity take-private transactions in healthcare this year.
- • The deal structure includes $76 per share in cash plus contingent value rights (CVRs) of up to $3 per share tied to breast health revenue milestones, potentially totaling $79 per share.
- • The transaction values Hologic, a Massachusetts-based women's health diagnostic company specializing in mammography, cervical cancer screening, and infectious disease detection, at above $75 per share.
- • The deal includes backing from major global institutional investors including Abu Dhabi Investment Authority (ADIA) and GIC, with a 45-day go-shop period permitting Hologic's board to solicit alternative bids.
- • Announcement is expected imminently, contingent on successful final negotiations, reflecting strong private equity conviction in diagnostic platform assets amid evolving medtech valuations.
Summary
Blackstone and TPG are in advanced negotiations to acquire Hologic, Inc. in a take-private transaction valued at more than $17 billion including debt, positioning the deal as one of the largest healthcare-focused private equity acquisitions of 2025. According to reporting from Bloomberg and corroborated by multiple sources, the parties are discussing a price exceeding $75 per share, with announcement expected as soon as the following week absent unforeseen obstacles.
The acquisition structure reflects a sophisticated deal architecture. Hologic shareholders will receive $76 per share in cash combined with contingent value rights (CVRs) providing up to $3 per share in two payments of up to $1.50 each, contingent upon achieving breast health revenue milestones. This structure totals potential consideration of up to $79 per share. The transaction has secured backing from prominent global institutional investors, including Abu Dhabi Investment Authority (ADIA) and GIC, signaling confidence in the acquisition thesis among sophisticated capital allocators.
Hologic, headquartered in Marlborough, Massachusetts, is a leading provider of diagnostic and imaging solutions focused on women's health. The company's portfolio spans breast cancer screening and diagnostics, cervical cancer testing, and infectious disease detection platforms, including COVID-19 diagnostics. Management has indicated the company will retain its brand identity and Massachusetts headquarters following completion of the transaction, positioning the combination as an evolution rather than a full operational restructuring.
The 45-day go-shop period embedded in the transaction framework permits Hologic's board to actively solicit alternative bids from competing bidders, providing a market check on valuation and deal terms. This mechanism is standard in large take-private transactions and underscores the board's fiduciary responsibilities to shareholders. The acquisition reflects broader private equity appetite for leadership positions in diagnostic platforms, driven by recognition of long-term value creation potential in women's health innovation and expanding diagnostic capabilities globally.
The acquisition structure reflects a sophisticated deal architecture. Hologic shareholders will receive $76 per share in cash combined with contingent value rights (CVRs) providing up to $3 per share in two payments of up to $1.50 each, contingent upon achieving breast health revenue milestones. This structure totals potential consideration of up to $79 per share. The transaction has secured backing from prominent global institutional investors, including Abu Dhabi Investment Authority (ADIA) and GIC, signaling confidence in the acquisition thesis among sophisticated capital allocators.
Hologic, headquartered in Marlborough, Massachusetts, is a leading provider of diagnostic and imaging solutions focused on women's health. The company's portfolio spans breast cancer screening and diagnostics, cervical cancer testing, and infectious disease detection platforms, including COVID-19 diagnostics. Management has indicated the company will retain its brand identity and Massachusetts headquarters following completion of the transaction, positioning the combination as an evolution rather than a full operational restructuring.
The 45-day go-shop period embedded in the transaction framework permits Hologic's board to actively solicit alternative bids from competing bidders, providing a market check on valuation and deal terms. This mechanism is standard in large take-private transactions and underscores the board's fiduciary responsibilities to shareholders. The acquisition reflects broader private equity appetite for leadership positions in diagnostic platforms, driven by recognition of long-term value creation potential in women's health innovation and expanding diagnostic capabilities globally.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.